Circulating cytokines and risk of developing hypertension: A systematic review and meta-analysis
Background: Immune responses play a significant role in hypertension, though the importance of key inflammatory mediators remains to be defined. We used a systematic literature review and meta-analysis to study the associations between key cytokines and incident hypertension. Methods: We performed a...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Elisabetta Caiazzo [verfasserIn] Malvika Sharma [verfasserIn] Asma O.M. Rezig [verfasserIn] Moustafa I. Morsy [verfasserIn] Marta Czesnikiewicz-Guzik [verfasserIn] Armando Ialenti [verfasserIn] Joanna Sulicka-Grodzicka [verfasserIn] Pierpaolo Pellicori [verfasserIn] Simone H. Crouch [verfasserIn] Aletta E. Schutte [verfasserIn] Dario Bruzzese [verfasserIn] Pasquale Maffia [verfasserIn] Tomasz J. Guzik [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2024 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Pharmacological Research ; 200(2024), Seite 107050- volume:200 ; year:2024 ; pages:107050- |
|---|
| Links: |
|---|
| DOI / URN: |
10.1016/j.phrs.2023.107050 |
|---|
| Katalog-ID: |
DOAJ094796467 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ094796467 | ||
| 003 | DE-627 | ||
| 005 | 20240413080221.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240413s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.phrs.2023.107050 |2 doi | |
| 035 | |a (DE-627)DOAJ094796467 | ||
| 035 | |a (DE-599)DOAJdb3992a9df8843ae86909267d3b99111 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RM1-950 | |
| 100 | 0 | |a Elisabetta Caiazzo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Circulating cytokines and risk of developing hypertension: A systematic review and meta-analysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background: Immune responses play a significant role in hypertension, though the importance of key inflammatory mediators remains to be defined. We used a systematic literature review and meta-analysis to study the associations between key cytokines and incident hypertension. Methods: We performed a systematic search of Pubmed/Medline, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials (CENTRAL), for peer-reviewed studies published up to August 2022. Incident hypertension was defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg and/or the use of antihypertensive medications. Random effects meta-analyses were used to calculate pooled hazard ratios (HRs)/risk ratios (RRs) and 95% confidence intervals by cytokine levels (highest vs. lowest quartile). Results: Only IL-6 and IL-1β levels have evidence allowing for quantitative evaluation concerning the onset of hypertension. Six studies (10406 participants, 2932 incident cases) examined the association of IL-6 with incident hypertension. The highest versus lowest quartile of circulating IL-6 was associated with a significant HR/RR of hypertension (1.61, 95% CI: 1.00 to 2.60; I2 =87%). After adjusting for potential confounders, including body mass index (BMI), HR/RR was no longer significant (HR/RR: 1.24; 95% CI, 0.96 to 1.61; I2 = 56%). About IL-1β, neither the crude (HR/RR: 1.03; 95% CI, 0.60 to 1.76; n = 2) nor multivariate analysis (HR/RR: 0.97, 95% CI, 0.60 to 1.56; n = 2) suggested a significant association with the risk of developing hypertension. Conclusions: A limited number of studies suggest that higher IL-6, but not IL-1β, might be associated with the development of hypertension. | ||
| 650 | 4 | |a Cytokines | |
| 650 | 4 | |a Incident hypertension | |
| 650 | 4 | |a Risk | |
| 650 | 4 | |a Systematic review | |
| 650 | 4 | |a Meta-analysis | |
| 653 | 0 | |a Therapeutics. Pharmacology | |
| 700 | 0 | |a Malvika Sharma |e verfasserin |4 aut | |
| 700 | 0 | |a Asma O.M. Rezig |e verfasserin |4 aut | |
| 700 | 0 | |a Moustafa I. Morsy |e verfasserin |4 aut | |
| 700 | 0 | |a Marta Czesnikiewicz-Guzik |e verfasserin |4 aut | |
| 700 | 0 | |a Armando Ialenti |e verfasserin |4 aut | |
| 700 | 0 | |a Joanna Sulicka-Grodzicka |e verfasserin |4 aut | |
| 700 | 0 | |a Pierpaolo Pellicori |e verfasserin |4 aut | |
| 700 | 0 | |a Simone H. Crouch |e verfasserin |4 aut | |
| 700 | 0 | |a Aletta E. Schutte |e verfasserin |4 aut | |
| 700 | 0 | |a Dario Bruzzese |e verfasserin |4 aut | |
| 700 | 0 | |a Pasquale Maffia |e verfasserin |4 aut | |
| 700 | 0 | |a Tomasz J. Guzik |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Pharmacological Research |g 200(2024), Seite 107050- |
| 773 | 1 | 8 | |g volume:200 |g year:2024 |g pages:107050- |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.phrs.2023.107050 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/db3992a9df8843ae86909267d3b99111 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1043661823004061 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1096-1186 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 200 |j 2024 |h 107050- | ||
| author_variant |
e c ec m s ms a o r aor m i m mim m c g mcg a i ai j s g jsg p p pp s h c shc a e s aes d b db p m pm t j g tjg |
|---|---|
| matchkey_str |
elisabettacaiazzomalvikasharmaasmaomrezi:2024----:icltnctknsnrsodvlpnhpresoaytmt |
| hierarchy_sort_str |
2024 |
| callnumber-subject-code |
RM |
| publishDate |
2024 |
| allfields |
10.1016/j.phrs.2023.107050 doi (DE-627)DOAJ094796467 (DE-599)DOAJdb3992a9df8843ae86909267d3b99111 DE-627 ger DE-627 rakwb eng RM1-950 Elisabetta Caiazzo verfasserin aut Circulating cytokines and risk of developing hypertension: A systematic review and meta-analysis 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Immune responses play a significant role in hypertension, though the importance of key inflammatory mediators remains to be defined. We used a systematic literature review and meta-analysis to study the associations between key cytokines and incident hypertension. Methods: We performed a systematic search of Pubmed/Medline, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials (CENTRAL), for peer-reviewed studies published up to August 2022. Incident hypertension was defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg and/or the use of antihypertensive medications. Random effects meta-analyses were used to calculate pooled hazard ratios (HRs)/risk ratios (RRs) and 95% confidence intervals by cytokine levels (highest vs. lowest quartile). Results: Only IL-6 and IL-1β levels have evidence allowing for quantitative evaluation concerning the onset of hypertension. Six studies (10406 participants, 2932 incident cases) examined the association of IL-6 with incident hypertension. The highest versus lowest quartile of circulating IL-6 was associated with a significant HR/RR of hypertension (1.61, 95% CI: 1.00 to 2.60; I2 =87%). After adjusting for potential confounders, including body mass index (BMI), HR/RR was no longer significant (HR/RR: 1.24; 95% CI, 0.96 to 1.61; I2 = 56%). About IL-1β, neither the crude (HR/RR: 1.03; 95% CI, 0.60 to 1.76; n = 2) nor multivariate analysis (HR/RR: 0.97, 95% CI, 0.60 to 1.56; n = 2) suggested a significant association with the risk of developing hypertension. Conclusions: A limited number of studies suggest that higher IL-6, but not IL-1β, might be associated with the development of hypertension. Cytokines Incident hypertension Risk Systematic review Meta-analysis Therapeutics. Pharmacology Malvika Sharma verfasserin aut Asma O.M. Rezig verfasserin aut Moustafa I. Morsy verfasserin aut Marta Czesnikiewicz-Guzik verfasserin aut Armando Ialenti verfasserin aut Joanna Sulicka-Grodzicka verfasserin aut Pierpaolo Pellicori verfasserin aut Simone H. Crouch verfasserin aut Aletta E. Schutte verfasserin aut Dario Bruzzese verfasserin aut Pasquale Maffia verfasserin aut Tomasz J. Guzik verfasserin aut In Pharmacological Research 200(2024), Seite 107050- volume:200 year:2024 pages:107050- https://doi.org/10.1016/j.phrs.2023.107050 kostenfrei https://doaj.org/article/db3992a9df8843ae86909267d3b99111 kostenfrei http://www.sciencedirect.com/science/article/pii/S1043661823004061 kostenfrei https://doaj.org/toc/1096-1186 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 200 2024 107050- |
| spelling |
10.1016/j.phrs.2023.107050 doi (DE-627)DOAJ094796467 (DE-599)DOAJdb3992a9df8843ae86909267d3b99111 DE-627 ger DE-627 rakwb eng RM1-950 Elisabetta Caiazzo verfasserin aut Circulating cytokines and risk of developing hypertension: A systematic review and meta-analysis 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Immune responses play a significant role in hypertension, though the importance of key inflammatory mediators remains to be defined. We used a systematic literature review and meta-analysis to study the associations between key cytokines and incident hypertension. Methods: We performed a systematic search of Pubmed/Medline, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials (CENTRAL), for peer-reviewed studies published up to August 2022. Incident hypertension was defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg and/or the use of antihypertensive medications. Random effects meta-analyses were used to calculate pooled hazard ratios (HRs)/risk ratios (RRs) and 95% confidence intervals by cytokine levels (highest vs. lowest quartile). Results: Only IL-6 and IL-1β levels have evidence allowing for quantitative evaluation concerning the onset of hypertension. Six studies (10406 participants, 2932 incident cases) examined the association of IL-6 with incident hypertension. The highest versus lowest quartile of circulating IL-6 was associated with a significant HR/RR of hypertension (1.61, 95% CI: 1.00 to 2.60; I2 =87%). After adjusting for potential confounders, including body mass index (BMI), HR/RR was no longer significant (HR/RR: 1.24; 95% CI, 0.96 to 1.61; I2 = 56%). About IL-1β, neither the crude (HR/RR: 1.03; 95% CI, 0.60 to 1.76; n = 2) nor multivariate analysis (HR/RR: 0.97, 95% CI, 0.60 to 1.56; n = 2) suggested a significant association with the risk of developing hypertension. Conclusions: A limited number of studies suggest that higher IL-6, but not IL-1β, might be associated with the development of hypertension. Cytokines Incident hypertension Risk Systematic review Meta-analysis Therapeutics. Pharmacology Malvika Sharma verfasserin aut Asma O.M. Rezig verfasserin aut Moustafa I. Morsy verfasserin aut Marta Czesnikiewicz-Guzik verfasserin aut Armando Ialenti verfasserin aut Joanna Sulicka-Grodzicka verfasserin aut Pierpaolo Pellicori verfasserin aut Simone H. Crouch verfasserin aut Aletta E. Schutte verfasserin aut Dario Bruzzese verfasserin aut Pasquale Maffia verfasserin aut Tomasz J. Guzik verfasserin aut In Pharmacological Research 200(2024), Seite 107050- volume:200 year:2024 pages:107050- https://doi.org/10.1016/j.phrs.2023.107050 kostenfrei https://doaj.org/article/db3992a9df8843ae86909267d3b99111 kostenfrei http://www.sciencedirect.com/science/article/pii/S1043661823004061 kostenfrei https://doaj.org/toc/1096-1186 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 200 2024 107050- |
| allfields_unstemmed |
10.1016/j.phrs.2023.107050 doi (DE-627)DOAJ094796467 (DE-599)DOAJdb3992a9df8843ae86909267d3b99111 DE-627 ger DE-627 rakwb eng RM1-950 Elisabetta Caiazzo verfasserin aut Circulating cytokines and risk of developing hypertension: A systematic review and meta-analysis 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Immune responses play a significant role in hypertension, though the importance of key inflammatory mediators remains to be defined. We used a systematic literature review and meta-analysis to study the associations between key cytokines and incident hypertension. Methods: We performed a systematic search of Pubmed/Medline, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials (CENTRAL), for peer-reviewed studies published up to August 2022. Incident hypertension was defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg and/or the use of antihypertensive medications. Random effects meta-analyses were used to calculate pooled hazard ratios (HRs)/risk ratios (RRs) and 95% confidence intervals by cytokine levels (highest vs. lowest quartile). Results: Only IL-6 and IL-1β levels have evidence allowing for quantitative evaluation concerning the onset of hypertension. Six studies (10406 participants, 2932 incident cases) examined the association of IL-6 with incident hypertension. The highest versus lowest quartile of circulating IL-6 was associated with a significant HR/RR of hypertension (1.61, 95% CI: 1.00 to 2.60; I2 =87%). After adjusting for potential confounders, including body mass index (BMI), HR/RR was no longer significant (HR/RR: 1.24; 95% CI, 0.96 to 1.61; I2 = 56%). About IL-1β, neither the crude (HR/RR: 1.03; 95% CI, 0.60 to 1.76; n = 2) nor multivariate analysis (HR/RR: 0.97, 95% CI, 0.60 to 1.56; n = 2) suggested a significant association with the risk of developing hypertension. Conclusions: A limited number of studies suggest that higher IL-6, but not IL-1β, might be associated with the development of hypertension. Cytokines Incident hypertension Risk Systematic review Meta-analysis Therapeutics. Pharmacology Malvika Sharma verfasserin aut Asma O.M. Rezig verfasserin aut Moustafa I. Morsy verfasserin aut Marta Czesnikiewicz-Guzik verfasserin aut Armando Ialenti verfasserin aut Joanna Sulicka-Grodzicka verfasserin aut Pierpaolo Pellicori verfasserin aut Simone H. Crouch verfasserin aut Aletta E. Schutte verfasserin aut Dario Bruzzese verfasserin aut Pasquale Maffia verfasserin aut Tomasz J. Guzik verfasserin aut In Pharmacological Research 200(2024), Seite 107050- volume:200 year:2024 pages:107050- https://doi.org/10.1016/j.phrs.2023.107050 kostenfrei https://doaj.org/article/db3992a9df8843ae86909267d3b99111 kostenfrei http://www.sciencedirect.com/science/article/pii/S1043661823004061 kostenfrei https://doaj.org/toc/1096-1186 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 200 2024 107050- |
| allfieldsGer |
10.1016/j.phrs.2023.107050 doi (DE-627)DOAJ094796467 (DE-599)DOAJdb3992a9df8843ae86909267d3b99111 DE-627 ger DE-627 rakwb eng RM1-950 Elisabetta Caiazzo verfasserin aut Circulating cytokines and risk of developing hypertension: A systematic review and meta-analysis 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Immune responses play a significant role in hypertension, though the importance of key inflammatory mediators remains to be defined. We used a systematic literature review and meta-analysis to study the associations between key cytokines and incident hypertension. Methods: We performed a systematic search of Pubmed/Medline, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials (CENTRAL), for peer-reviewed studies published up to August 2022. Incident hypertension was defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg and/or the use of antihypertensive medications. Random effects meta-analyses were used to calculate pooled hazard ratios (HRs)/risk ratios (RRs) and 95% confidence intervals by cytokine levels (highest vs. lowest quartile). Results: Only IL-6 and IL-1β levels have evidence allowing for quantitative evaluation concerning the onset of hypertension. Six studies (10406 participants, 2932 incident cases) examined the association of IL-6 with incident hypertension. The highest versus lowest quartile of circulating IL-6 was associated with a significant HR/RR of hypertension (1.61, 95% CI: 1.00 to 2.60; I2 =87%). After adjusting for potential confounders, including body mass index (BMI), HR/RR was no longer significant (HR/RR: 1.24; 95% CI, 0.96 to 1.61; I2 = 56%). About IL-1β, neither the crude (HR/RR: 1.03; 95% CI, 0.60 to 1.76; n = 2) nor multivariate analysis (HR/RR: 0.97, 95% CI, 0.60 to 1.56; n = 2) suggested a significant association with the risk of developing hypertension. Conclusions: A limited number of studies suggest that higher IL-6, but not IL-1β, might be associated with the development of hypertension. Cytokines Incident hypertension Risk Systematic review Meta-analysis Therapeutics. Pharmacology Malvika Sharma verfasserin aut Asma O.M. Rezig verfasserin aut Moustafa I. Morsy verfasserin aut Marta Czesnikiewicz-Guzik verfasserin aut Armando Ialenti verfasserin aut Joanna Sulicka-Grodzicka verfasserin aut Pierpaolo Pellicori verfasserin aut Simone H. Crouch verfasserin aut Aletta E. Schutte verfasserin aut Dario Bruzzese verfasserin aut Pasquale Maffia verfasserin aut Tomasz J. Guzik verfasserin aut In Pharmacological Research 200(2024), Seite 107050- volume:200 year:2024 pages:107050- https://doi.org/10.1016/j.phrs.2023.107050 kostenfrei https://doaj.org/article/db3992a9df8843ae86909267d3b99111 kostenfrei http://www.sciencedirect.com/science/article/pii/S1043661823004061 kostenfrei https://doaj.org/toc/1096-1186 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 200 2024 107050- |
| allfieldsSound |
10.1016/j.phrs.2023.107050 doi (DE-627)DOAJ094796467 (DE-599)DOAJdb3992a9df8843ae86909267d3b99111 DE-627 ger DE-627 rakwb eng RM1-950 Elisabetta Caiazzo verfasserin aut Circulating cytokines and risk of developing hypertension: A systematic review and meta-analysis 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Immune responses play a significant role in hypertension, though the importance of key inflammatory mediators remains to be defined. We used a systematic literature review and meta-analysis to study the associations between key cytokines and incident hypertension. Methods: We performed a systematic search of Pubmed/Medline, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials (CENTRAL), for peer-reviewed studies published up to August 2022. Incident hypertension was defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg and/or the use of antihypertensive medications. Random effects meta-analyses were used to calculate pooled hazard ratios (HRs)/risk ratios (RRs) and 95% confidence intervals by cytokine levels (highest vs. lowest quartile). Results: Only IL-6 and IL-1β levels have evidence allowing for quantitative evaluation concerning the onset of hypertension. Six studies (10406 participants, 2932 incident cases) examined the association of IL-6 with incident hypertension. The highest versus lowest quartile of circulating IL-6 was associated with a significant HR/RR of hypertension (1.61, 95% CI: 1.00 to 2.60; I2 =87%). After adjusting for potential confounders, including body mass index (BMI), HR/RR was no longer significant (HR/RR: 1.24; 95% CI, 0.96 to 1.61; I2 = 56%). About IL-1β, neither the crude (HR/RR: 1.03; 95% CI, 0.60 to 1.76; n = 2) nor multivariate analysis (HR/RR: 0.97, 95% CI, 0.60 to 1.56; n = 2) suggested a significant association with the risk of developing hypertension. Conclusions: A limited number of studies suggest that higher IL-6, but not IL-1β, might be associated with the development of hypertension. Cytokines Incident hypertension Risk Systematic review Meta-analysis Therapeutics. Pharmacology Malvika Sharma verfasserin aut Asma O.M. Rezig verfasserin aut Moustafa I. Morsy verfasserin aut Marta Czesnikiewicz-Guzik verfasserin aut Armando Ialenti verfasserin aut Joanna Sulicka-Grodzicka verfasserin aut Pierpaolo Pellicori verfasserin aut Simone H. Crouch verfasserin aut Aletta E. Schutte verfasserin aut Dario Bruzzese verfasserin aut Pasquale Maffia verfasserin aut Tomasz J. Guzik verfasserin aut In Pharmacological Research 200(2024), Seite 107050- volume:200 year:2024 pages:107050- https://doi.org/10.1016/j.phrs.2023.107050 kostenfrei https://doaj.org/article/db3992a9df8843ae86909267d3b99111 kostenfrei http://www.sciencedirect.com/science/article/pii/S1043661823004061 kostenfrei https://doaj.org/toc/1096-1186 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 200 2024 107050- |
| language |
English |
| source |
In Pharmacological Research 200(2024), Seite 107050- volume:200 year:2024 pages:107050- |
| sourceStr |
In Pharmacological Research 200(2024), Seite 107050- volume:200 year:2024 pages:107050- |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Cytokines Incident hypertension Risk Systematic review Meta-analysis Therapeutics. Pharmacology |
| isfreeaccess_bool |
true |
| container_title |
Pharmacological Research |
| authorswithroles_txt_mv |
Elisabetta Caiazzo @@aut@@ Malvika Sharma @@aut@@ Asma O.M. Rezig @@aut@@ Moustafa I. Morsy @@aut@@ Marta Czesnikiewicz-Guzik @@aut@@ Armando Ialenti @@aut@@ Joanna Sulicka-Grodzicka @@aut@@ Pierpaolo Pellicori @@aut@@ Simone H. Crouch @@aut@@ Aletta E. Schutte @@aut@@ Dario Bruzzese @@aut@@ Pasquale Maffia @@aut@@ Tomasz J. Guzik @@aut@@ |
| publishDateDaySort_date |
2024-01-01T00:00:00Z |
| id |
DOAJ094796467 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ094796467</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413080221.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2024 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.phrs.2023.107050</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ094796467</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJdb3992a9df8843ae86909267d3b99111</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Elisabetta Caiazzo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Circulating cytokines and risk of developing hypertension: A systematic review and meta-analysis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2024</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: Immune responses play a significant role in hypertension, though the importance of key inflammatory mediators remains to be defined. We used a systematic literature review and meta-analysis to study the associations between key cytokines and incident hypertension. Methods: We performed a systematic search of Pubmed/Medline, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials (CENTRAL), for peer-reviewed studies published up to August 2022. Incident hypertension was defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg and/or the use of antihypertensive medications. Random effects meta-analyses were used to calculate pooled hazard ratios (HRs)/risk ratios (RRs) and 95% confidence intervals by cytokine levels (highest vs. lowest quartile). Results: Only IL-6 and IL-1β levels have evidence allowing for quantitative evaluation concerning the onset of hypertension. Six studies (10406 participants, 2932 incident cases) examined the association of IL-6 with incident hypertension. The highest versus lowest quartile of circulating IL-6 was associated with a significant HR/RR of hypertension (1.61, 95% CI: 1.00 to 2.60; I2 =87%). After adjusting for potential confounders, including body mass index (BMI), HR/RR was no longer significant (HR/RR: 1.24; 95% CI, 0.96 to 1.61; I2 = 56%). About IL-1β, neither the crude (HR/RR: 1.03; 95% CI, 0.60 to 1.76; n = 2) nor multivariate analysis (HR/RR: 0.97, 95% CI, 0.60 to 1.56; n = 2) suggested a significant association with the risk of developing hypertension. Conclusions: A limited number of studies suggest that higher IL-6, but not IL-1β, might be associated with the development of hypertension.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cytokines</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Incident hypertension</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Risk</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Systematic review</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Meta-analysis</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Malvika Sharma</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Asma O.M. Rezig</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Moustafa I. Morsy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marta Czesnikiewicz-Guzik</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Armando Ialenti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Joanna Sulicka-Grodzicka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pierpaolo Pellicori</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Simone H. Crouch</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Aletta E. Schutte</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dario Bruzzese</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pasquale Maffia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tomasz J. Guzik</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Pharmacological Research</subfield><subfield code="g">200(2024), Seite 107050-</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:200</subfield><subfield code="g">year:2024</subfield><subfield code="g">pages:107050-</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.phrs.2023.107050</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/db3992a9df8843ae86909267d3b99111</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S1043661823004061</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1096-1186</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">200</subfield><subfield code="j">2024</subfield><subfield code="h">107050-</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
Elisabetta Caiazzo |
| spellingShingle |
Elisabetta Caiazzo misc RM1-950 misc Cytokines misc Incident hypertension misc Risk misc Systematic review misc Meta-analysis misc Therapeutics. Pharmacology Circulating cytokines and risk of developing hypertension: A systematic review and meta-analysis |
| authorStr |
Elisabetta Caiazzo |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RM1-950 |
| illustrated |
Not Illustrated |
| topic_title |
RM1-950 Circulating cytokines and risk of developing hypertension: A systematic review and meta-analysis Cytokines Incident hypertension Risk Systematic review Meta-analysis |
| topic |
misc RM1-950 misc Cytokines misc Incident hypertension misc Risk misc Systematic review misc Meta-analysis misc Therapeutics. Pharmacology |
| topic_unstemmed |
misc RM1-950 misc Cytokines misc Incident hypertension misc Risk misc Systematic review misc Meta-analysis misc Therapeutics. Pharmacology |
| topic_browse |
misc RM1-950 misc Cytokines misc Incident hypertension misc Risk misc Systematic review misc Meta-analysis misc Therapeutics. Pharmacology |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Pharmacological Research |
| hierarchy_top_title |
Pharmacological Research |
| isfreeaccess_txt |
true |
| title |
Circulating cytokines and risk of developing hypertension: A systematic review and meta-analysis |
| ctrlnum |
(DE-627)DOAJ094796467 (DE-599)DOAJdb3992a9df8843ae86909267d3b99111 |
| title_full |
Circulating cytokines and risk of developing hypertension: A systematic review and meta-analysis |
| author_sort |
Elisabetta Caiazzo |
| journal |
Pharmacological Research |
| journalStr |
Pharmacological Research |
| callnumber-first-code |
R |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2024 |
| contenttype_str_mv |
txt |
| container_start_page |
107050 |
| author_browse |
Elisabetta Caiazzo Malvika Sharma Asma O.M. Rezig Moustafa I. Morsy Marta Czesnikiewicz-Guzik Armando Ialenti Joanna Sulicka-Grodzicka Pierpaolo Pellicori Simone H. Crouch Aletta E. Schutte Dario Bruzzese Pasquale Maffia Tomasz J. Guzik |
| container_volume |
200 |
| class |
RM1-950 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Elisabetta Caiazzo |
| doi_str_mv |
10.1016/j.phrs.2023.107050 |
| author2-role |
verfasserin |
| title_sort |
circulating cytokines and risk of developing hypertension: a systematic review and meta-analysis |
| callnumber |
RM1-950 |
| title_auth |
Circulating cytokines and risk of developing hypertension: A systematic review and meta-analysis |
| abstract |
Background: Immune responses play a significant role in hypertension, though the importance of key inflammatory mediators remains to be defined. We used a systematic literature review and meta-analysis to study the associations between key cytokines and incident hypertension. Methods: We performed a systematic search of Pubmed/Medline, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials (CENTRAL), for peer-reviewed studies published up to August 2022. Incident hypertension was defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg and/or the use of antihypertensive medications. Random effects meta-analyses were used to calculate pooled hazard ratios (HRs)/risk ratios (RRs) and 95% confidence intervals by cytokine levels (highest vs. lowest quartile). Results: Only IL-6 and IL-1β levels have evidence allowing for quantitative evaluation concerning the onset of hypertension. Six studies (10406 participants, 2932 incident cases) examined the association of IL-6 with incident hypertension. The highest versus lowest quartile of circulating IL-6 was associated with a significant HR/RR of hypertension (1.61, 95% CI: 1.00 to 2.60; I2 =87%). After adjusting for potential confounders, including body mass index (BMI), HR/RR was no longer significant (HR/RR: 1.24; 95% CI, 0.96 to 1.61; I2 = 56%). About IL-1β, neither the crude (HR/RR: 1.03; 95% CI, 0.60 to 1.76; n = 2) nor multivariate analysis (HR/RR: 0.97, 95% CI, 0.60 to 1.56; n = 2) suggested a significant association with the risk of developing hypertension. Conclusions: A limited number of studies suggest that higher IL-6, but not IL-1β, might be associated with the development of hypertension. |
| abstractGer |
Background: Immune responses play a significant role in hypertension, though the importance of key inflammatory mediators remains to be defined. We used a systematic literature review and meta-analysis to study the associations between key cytokines and incident hypertension. Methods: We performed a systematic search of Pubmed/Medline, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials (CENTRAL), for peer-reviewed studies published up to August 2022. Incident hypertension was defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg and/or the use of antihypertensive medications. Random effects meta-analyses were used to calculate pooled hazard ratios (HRs)/risk ratios (RRs) and 95% confidence intervals by cytokine levels (highest vs. lowest quartile). Results: Only IL-6 and IL-1β levels have evidence allowing for quantitative evaluation concerning the onset of hypertension. Six studies (10406 participants, 2932 incident cases) examined the association of IL-6 with incident hypertension. The highest versus lowest quartile of circulating IL-6 was associated with a significant HR/RR of hypertension (1.61, 95% CI: 1.00 to 2.60; I2 =87%). After adjusting for potential confounders, including body mass index (BMI), HR/RR was no longer significant (HR/RR: 1.24; 95% CI, 0.96 to 1.61; I2 = 56%). About IL-1β, neither the crude (HR/RR: 1.03; 95% CI, 0.60 to 1.76; n = 2) nor multivariate analysis (HR/RR: 0.97, 95% CI, 0.60 to 1.56; n = 2) suggested a significant association with the risk of developing hypertension. Conclusions: A limited number of studies suggest that higher IL-6, but not IL-1β, might be associated with the development of hypertension. |
| abstract_unstemmed |
Background: Immune responses play a significant role in hypertension, though the importance of key inflammatory mediators remains to be defined. We used a systematic literature review and meta-analysis to study the associations between key cytokines and incident hypertension. Methods: We performed a systematic search of Pubmed/Medline, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials (CENTRAL), for peer-reviewed studies published up to August 2022. Incident hypertension was defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg and/or the use of antihypertensive medications. Random effects meta-analyses were used to calculate pooled hazard ratios (HRs)/risk ratios (RRs) and 95% confidence intervals by cytokine levels (highest vs. lowest quartile). Results: Only IL-6 and IL-1β levels have evidence allowing for quantitative evaluation concerning the onset of hypertension. Six studies (10406 participants, 2932 incident cases) examined the association of IL-6 with incident hypertension. The highest versus lowest quartile of circulating IL-6 was associated with a significant HR/RR of hypertension (1.61, 95% CI: 1.00 to 2.60; I2 =87%). After adjusting for potential confounders, including body mass index (BMI), HR/RR was no longer significant (HR/RR: 1.24; 95% CI, 0.96 to 1.61; I2 = 56%). About IL-1β, neither the crude (HR/RR: 1.03; 95% CI, 0.60 to 1.76; n = 2) nor multivariate analysis (HR/RR: 0.97, 95% CI, 0.60 to 1.56; n = 2) suggested a significant association with the risk of developing hypertension. Conclusions: A limited number of studies suggest that higher IL-6, but not IL-1β, might be associated with the development of hypertension. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| title_short |
Circulating cytokines and risk of developing hypertension: A systematic review and meta-analysis |
| url |
https://doi.org/10.1016/j.phrs.2023.107050 https://doaj.org/article/db3992a9df8843ae86909267d3b99111 http://www.sciencedirect.com/science/article/pii/S1043661823004061 https://doaj.org/toc/1096-1186 |
| remote_bool |
true |
| author2 |
Malvika Sharma Asma O.M. Rezig Moustafa I. Morsy Marta Czesnikiewicz-Guzik Armando Ialenti Joanna Sulicka-Grodzicka Pierpaolo Pellicori Simone H. Crouch Aletta E. Schutte Dario Bruzzese Pasquale Maffia Tomasz J. Guzik |
| author2Str |
Malvika Sharma Asma O.M. Rezig Moustafa I. Morsy Marta Czesnikiewicz-Guzik Armando Ialenti Joanna Sulicka-Grodzicka Pierpaolo Pellicori Simone H. Crouch Aletta E. Schutte Dario Bruzzese Pasquale Maffia Tomasz J. Guzik |
| callnumber-subject |
RM - Therapeutics and Pharmacology |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1016/j.phrs.2023.107050 |
| callnumber-a |
RM1-950 |
| up_date |
2024-07-04T00:43:18.547Z |
| _version_ |
1803607131867316224 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ094796467</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413080221.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2024 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.phrs.2023.107050</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ094796467</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJdb3992a9df8843ae86909267d3b99111</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Elisabetta Caiazzo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Circulating cytokines and risk of developing hypertension: A systematic review and meta-analysis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2024</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: Immune responses play a significant role in hypertension, though the importance of key inflammatory mediators remains to be defined. We used a systematic literature review and meta-analysis to study the associations between key cytokines and incident hypertension. Methods: We performed a systematic search of Pubmed/Medline, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials (CENTRAL), for peer-reviewed studies published up to August 2022. Incident hypertension was defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg and/or the use of antihypertensive medications. Random effects meta-analyses were used to calculate pooled hazard ratios (HRs)/risk ratios (RRs) and 95% confidence intervals by cytokine levels (highest vs. lowest quartile). Results: Only IL-6 and IL-1β levels have evidence allowing for quantitative evaluation concerning the onset of hypertension. Six studies (10406 participants, 2932 incident cases) examined the association of IL-6 with incident hypertension. The highest versus lowest quartile of circulating IL-6 was associated with a significant HR/RR of hypertension (1.61, 95% CI: 1.00 to 2.60; I2 =87%). After adjusting for potential confounders, including body mass index (BMI), HR/RR was no longer significant (HR/RR: 1.24; 95% CI, 0.96 to 1.61; I2 = 56%). About IL-1β, neither the crude (HR/RR: 1.03; 95% CI, 0.60 to 1.76; n = 2) nor multivariate analysis (HR/RR: 0.97, 95% CI, 0.60 to 1.56; n = 2) suggested a significant association with the risk of developing hypertension. Conclusions: A limited number of studies suggest that higher IL-6, but not IL-1β, might be associated with the development of hypertension.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cytokines</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Incident hypertension</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Risk</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Systematic review</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Meta-analysis</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Malvika Sharma</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Asma O.M. Rezig</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Moustafa I. Morsy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marta Czesnikiewicz-Guzik</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Armando Ialenti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Joanna Sulicka-Grodzicka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pierpaolo Pellicori</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Simone H. Crouch</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Aletta E. Schutte</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dario Bruzzese</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pasquale Maffia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tomasz J. Guzik</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Pharmacological Research</subfield><subfield code="g">200(2024), Seite 107050-</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:200</subfield><subfield code="g">year:2024</subfield><subfield code="g">pages:107050-</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.phrs.2023.107050</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/db3992a9df8843ae86909267d3b99111</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S1043661823004061</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1096-1186</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">200</subfield><subfield code="j">2024</subfield><subfield code="h">107050-</subfield></datafield></record></collection>
|
| score |
7.401292 |